![fac-[Re(CO)3(L6)(H2O)][NO3]](https://file.medchemexpress.com/product_pic/hy-155718.gif "Click to View fac-[Re(CO)3(L6)(H2O)][NO3] Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1101 Results for "
Anticancer agent
" in MedChemExpress (MCE) Product Catalog:
Products (1101)
1101 Results for "Anticancer agent" in MCE Product Catalog:
Cat. No.: HY-182241
CAS No.: 2446965-01-9
Research Areas:
JR4-187 is an orally active, copper-dependent anticancer agent. JR4-187 downregulates genes involved in oxidative phosphorylation, MYC targets and E2F targets in cancer cells, while upregulates genes involved in the TNF-α signaling pathway, p53 pathway and KRAS signaling pathway, and downregulates CTR1 protein . JR4-187 induces ROS production, apoptosis, copper-dependent cytotoxicity, and exhibits selective cytotoxicity against KRAS-mutant cancer cells. JR4-187 is well tolerated in mouse models of pancreatic cancer. JR4-187 can be used in research related to cancers such as pancreatic ductal adenocarcinoma, colon cancer and rectal cancer .
Cat. No.: HY-N15415
CAS No.: 16838-87-2
Cat. No.: HY-N3387
CAS No.: 30508-27-1
Cat. No.: HY-N6017
CAS No.: 19906-72-0
Cat. No.: HY-N6746S1
Synonyms: NSC 186-13C13
Cat. No.: HY-P991342
Synonyms: PCA062 antibody
Cat. No.: HY-W027592R
CAS No.: 61-82-5
Cat. No.: HY-N20674
CAS No.: 76472-89-4
Category:
Cat. No.: HY-121605S
Cat. No.: HY-181099
EGFR WT/T790M-IN-4 is an anticancer agent. EGFR WT/T790M-IN-4 acts as an inhibitor of EGFR WT and EGFR T790M , with an IC50 of 0.133 μM and 0.043 μM, respectively. EGFR WT/T790M-IN-4 also inhibits PI3K and mTOR kinases, with IC50 values of 0.22 μM and 0.35 μM, respectively. EGFR WT/T790M-IN-4 induces cell cycle arrest and apoptosis in cancer cells, and inhibits cancer cell proliferation. EGFR WT/T790M-IN-4 can be used in research related to prostate cancer, colon cancer and breast cancer .
Cat. No.: HY-P12127
CAS No.: 233273-63-7
Synonyms: BF2-B
Buforin IIb (BF2-B) is an anticancer peptide, as well as an Antibacterial and Antifungal agent. Buforin IIb is derived from histone H2A. Buforin IIb activates SAPK/JNK and p38 MAPK. Buforin IIb induces mitochondria-dependent Apoptosis . Buforin IIb achieves selective targeting by interacting with gangliosides on the surface of cancer cells, and can penetrate cancer cell membranes without causing damage. Buforin IIb exhibits antibacterial activity against Gram-negative bacteria, Gram-positive bacteria and fungi. Buforin IIb can be used in the research of cervical cancer, as well as cancers including leukemia, central nervous system cancer, ovarian cancer, breast cancer, melanoma, colon cancer, non-small cell lung cancer, renal cancer and prostate cancer .
Cat. No.: HY-W017424R
CAS No.: 136-95-8
Research Areas:
2-Aminobenzothiazole (Standard) is the analytical standard of 2-Aminobenzothiazole. This product is intended for research and analytical applications. 2-Aminobenzothiazole acts as a caspase 3/7 activator, an anticancer cytotoxic agent, and also exhibits neurotoxicity. 2-Aminobenzothiazole drives the apoptotic pathway by activating caspase 3/7, induces mitochondrial inner membrane depolarization, and triggers both early and late apoptosis via a caspase-dependent pathway. In zebrafish models, 2-Aminobenzothiazole induces oxidative damage in brain tissues and inhibits genes related to GABA and 5-HT synthesis pathways. Long-term exposure to 2-Aminobenzothiazole impairs motor ability, social behavior, anxiety-like state and cognitive function. 2-Aminobenzothiazole can be used in studies of human laryngeal carcinoma and related neurotoxicity .
Cat. No.: HY-13774
CAS No.: 908859-10-9
Target:
Research Areas:
WK-X-34 is a low-toxicity, highly effective multidrug resistance reversal agent. By potently inhibiting the transport functions of P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP), WK-X-34 significantly increases the intracellular accumulation of anticancer drugs and radiotracers in drug-resistant cells. WK-X-34 exerts no significant effect on MRP transporters. WK-X-34 not only restores the chemosensitivity of multidrug-resistant ovarian cancer cells, but also significantly enhances the uptake of 99mTc-Sestamibi in P-gp-positive xenograft tumors, brain and intestinal tissues. WK-X-34 exhibits extremely low toxicity and favorable safety profiles both in vitro and in mice (at doses up to 50 mg/kg), and can be used for research on overcoming multidrug resistance in ovarian cancer .
Cat. No.: HY-155718
fac-[Re(CO)3(L6)(H2O)][NO3] (compound 6), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L6)(H2O)][NO3] is cytotoxic to prostate cancer cells, IC50=50 nM (PC-3 cells). fac-[Re(CO)3(L6)(H2O)][NO3] mainly accumulates in the nucleus, down-regulates ATP production in PC3 cells, and promotes apoptosis. However, fac-[Re(CO)3(L6)(H2O)][NO3] did not induce necrosis, pyrodeath and autophagy .
Cat. No.: HY-179052
Research Areas:
Apoptosis inducer 50 (Compound 5e) is an apoptosis inducer as well as an autophagy inducer agent. Apoptosis inducer 50 exhibits potent and selective anti-cancer activity against triple-negative breast cancer cells and metastatic colon cancer cells. Apoptosis inducer 50 upregulates the expression of pro-apoptotic proteins (Bax, Bim, cleaved Caspase-9) and downregulates the expression of the anti-apoptotic protein (BCL-XL). Apoptosis inducer 50 upregulates key autophagy markers such as Beclin-1 and ATG5, and enhances the conversion of LC3-I to LC3-II., Apoptosis inducer 50 arrests cancer cells in the G1/S phase by upregulating the expression of p21 and p27 while downregulating Cyclin D1. Apoptosis inducer 50 increases the level of ROS .
Cat. No.: HY-183402
CAS No.: 917813-60-6
Synonyms: GO-Y026
Target:
Research Areas:
FLLL12 (GO-Y026) is a curcumin analog anticancer agent. FLLL12 inhibits the phosphorylation of AKT, Bcl-2, Bid, EGFR, mTOR, FOXO1a, FOXO3a, STAT3, HER2/neu, as well as pancreatic AKT/STAT3; upregulates the expression of Bim and DR5; and activates PTPs. FLLL12 regulates downstream pathways, induces mitochondria-mediated and DR5-dependent extrinsic apoptosis, inhibits cancer cell viability, proliferation, anchorage-independent growth and migration, and exerts a synergistic effect with Doxorubicin (HY-15142A). FLLL12 can be used in research related to head and neck squamous cell carcinoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, colon cancer and colorectal cancer .
Research Areas:
p-Toluenesulfonamide is a small-molecule anticancer agent and plasticizer. p-Toluenesulfonamide exerts antitumor activity by inducing lysosomal membrane permeabilization, cathepsin B release and lysosome-mediated cell death. p-Toluenesulfonamide modulates cholesterol distribution in lipid rafts of tumor cell membranes and the Akt/mTOR/p70S6K pathway. p-Toluenesulfonamide shows activity against various cancers including hepatocellular carcinoma, non-small cell lung cancer and tongue squamous cell carcinoma; intrapleural injection effectively reduces malignant pleural effusion without causing pleural adhesion. p-Toluenesulfonamide is also the main degradation product of the disinfectant Chloramine-T (HY-B0959) in water. p-Toluenesulfonamide facilitates the localization of fluorescent probes to the endoplasmic reticulum. p-Toluenesulfonamide can be used in cancer-related research .
Cat. No.: HY-P12127A
Synonyms: BF2-B TFA
Buforin IIb TFA (BF2-B TFA) is an anticancer peptide, as well as an Antibacterial and Antifungal agent. Buforin IIb TFA is derived from histone H2A. Buforin IIb TFA activates SAPK/JNK and p38 MAPK. Buforin IIb TFA induces mitochondria-dependent Apoptosis . Buforin IIb TFA achieves selective targeting by interacting with gangliosides on the surface of cancer cells, and can penetrate cancer cell membranes without causing damage. Buforin IIb TFA exhibits antibacterial activity against Gram-negative bacteria, Gram-positive bacteria and fungi. Buforin IIb TFA can be used in the research of cervical cancer, as well as cancers including leukemia, central nervous system cancer, ovarian cancer, breast cancer, melanoma, colon cancer, non-small cell lung cancer, renal cancer and prostate cancer .
Target:
Research Areas:
DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
Cat. No.: HY-114243A
CAS No.: 1382469-40-0
Target:
Research Areas:
Neurological Disease Inflammation/Immunology Endocrinology Cancer
DpC hydrochloride is a selective, orally active iron chelator with anticancer activity. DpC hydrochloride acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC hydrochloride induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC hydrochloride inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC hydrochloride is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
